A268600 Stock Overview
Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening diseases comprising cancer, inflammation, metabolic, and neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cellivery Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,680.00 |
| 52 Week High | ₩20,900.00 |
| 52 Week Low | ₩6,680.00 |
| Beta | 0.50 |
| 11 Month Change | 0% |
| 3 Month Change | -29.91% |
| 1 Year Change | -45.36% |
| 33 Year Change | -74.58% |
| 5 Year Change | n/a |
| Change since IPO | -6.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| A268600 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | 2.9% |
| 1Y | -45.4% | 33.7% | -2.8% |
Return vs Industry: A268600 underperformed the KR Life Sciences industry which returned -13% over the past year.
Return vs Market: A268600 underperformed the KR Market which returned 8% over the past year.
Price Volatility
| A268600 volatility | |
|---|---|
| A268600 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A268600's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A268600's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 100 | Daewoong Jo | www.cellivery.com |
Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening diseases comprising cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its therapeutic molecule systemic delivery technology. The company was incorporated in 2014 and is based in Seoul, South Korea.
Cellivery Therapeutics, Inc. Fundamentals Summary
| A268600 fundamental statistics | |
|---|---|
| Market cap | ₩244.94b |
| Earnings (TTM) | -₩73.70b |
| Revenue (TTM) | ₩22.57b |
10.9x
P/S Ratio-3.3x
P/E RatioIs A268600 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A268600 income statement (TTM) | |
|---|---|
| Revenue | ₩22.57b |
| Cost of Revenue | ₩23.15b |
| Gross Profit | -₩578.02m |
| Other Expenses | ₩73.12b |
| Earnings | -₩73.70b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01k |
| Gross Margin | -2.56% |
| Net Profit Margin | -326.54% |
| Debt/Equity Ratio | -979.5% |
How did A268600 perform over the long term?
See historical performance and comparison